Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Gross Profit (2018 - 2025)

BioNexus Gene Lab's Gross Profit history spans 8 years, with the latest figure at $377685.0 for Q3 2025.

  • For Q3 2025, Gross Profit rose 15.66% year-over-year to $377685.0; the TTM value through Sep 2025 reached $1.4 million, up 12.16%, while the annual FY2024 figure was $1.3 million, 3.01% down from the prior year.
  • Gross Profit for Q3 2025 was $377685.0 at BioNexus Gene Lab, up from $368022.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $709194.0 in Q3 2021 and bottomed at $263971.0 in Q2 2022.
  • The 5-year median for Gross Profit is $354332.0 (2023), against an average of $384143.5.
  • The largest YoY upside for Gross Profit was 4440.14% in 2021 against a maximum downside of 69.54% in 2021.
  • A 5-year view of Gross Profit shows it stood at $528670.0 in 2021, then crashed by 35.83% to $339226.0 in 2022, then dropped by 21.42% to $266555.0 in 2023, then grew by 16.01% to $309234.0 in 2024, then increased by 22.14% to $377685.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Gross Profit are $377685.0 (Q3 2025), $368022.0 (Q2 2025), and $343493.0 (Q1 2025).